MeiraGTx Holdings PLC (MGTX) – What Are Researchers Saying About This Stock?

Posted by Stanley Muller on Oct 27th, 2026

MeiraGTx Holdings PLC (NASDAQ:MGTX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the eight analysts that are currently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $24.00.

MGTX has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of MeiraGTx from a “hold” rating to a “buy” rating in a report on Saturday. Zacks Research lowered MeiraGTx from a “strong-buy” rating to a “hold” rating in a report on Friday, September 11th. Weiss Ratings raised MeiraGTx from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Royal Bank Of Canada lifted their price target on MeiraGTx from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Friday, August 14th. Finally, The Goldman Sachs Group initiated coverage on MeiraGTx in a research note on Thursday, September 24th. They issued a “neutral” rating and a $16.00 price objective for the company.

Check Out Our Latest Report on MeiraGTx

Insider Buying and Selling at MeiraGTx

In related news, insider Stuart Naylor sold 27,659 shares of the firm’s stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $10.64, for a total value of $294,291.76. Following the transaction, the insider directly owned 613,187 shares of the company’s stock, valued at approximately $6,524,309.68. This trade represents a 4.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Richard Giroux sold 56,000 shares of the company’s stock in a transaction on Tuesday, October 20th. The stock was sold at an average price of $9.95, for a total transaction of $557,200.00. Following the sale, the chief financial officer directly owned 852,530 shares of the company’s stock, valued at approximately $8,482,673.50. This represents a 6.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 145,659 shares of company stock worth $1,710,812. 7.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On MeiraGTx

Several large investors have recently bought and sold shares of the stock. Squarepoint Ops LLC raised its holdings in MeiraGTx by 773.9% in the 2nd quarter. Squarepoint Ops LLC now owns 162,412 shares of the company’s stock valued at $2,194,000 after acquiring an additional 143,828 shares in the last quarter. Tocqueville Asset Management L.P. acquired a new position in shares of MeiraGTx during the second quarter worth approximately $1,050,000. Johnson & Johnson acquired a new stake in shares of MeiraGTx in the 2nd quarter valued at $89,720,775. Sei Investments Co. bought a new stake in MeiraGTx during the 1st quarter worth about $863,000. Finally, Bank of America Corp DE bought a new position in MeiraGTx in the second quarter valued at approximately $3,914,000. 67.48% of the stock is currently owned by institutional investors and hedge funds.

MeiraGTx Trading Down 0.3%

Shares of MGTX stock opened at $9.18 on Tuesday. The stock has a 50-day simple moving average of $12.09 and a 200 day simple moving average of $10.24. The stock has a market capitalization of $881.65 million, a P/E ratio of 12.93 and a beta of 1.35. MeiraGTx has a fifty-two week low of $6.62 and a fifty-two week high of $15.35. The company has a quick ratio of 3.76, a current ratio of 3.76 and a debt-to-equity ratio of 0.46.

MeiraGTx (NASDAQ:MGTX – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported $1.71 EPS for the quarter, topping the consensus estimate of ($0.46) by $2.17. MeiraGTx had a net margin of 19.87% and a return on equity of 283.85%. The firm had revenue of $321.43 million for the quarter, compared to analysts’ expectations of $0.70 million. On average, sell-side analysts expect that MeiraGTx will post 0.30 earnings per share for the current fiscal year.

MeiraGTx Company Profile

(Get Free Report)

MeiraGTx Holdings plc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases with limited treatment options. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes to targeted tissues and address the underlying causes of disease.

Its research and development activities have focused primarily on disorders of the central nervous system, including neurodegenerative diseases, as well as retinal and salivary-gland conditions.